The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
Open Access
- 30 September 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (13), 2286-2294
- https://doi.org/10.1182/blood-2010-02-271874
Abstract
T-cell expression of programmed death receptor-1 (PD-1) down-regulates the immune response against malignancy by interacting with cognate ligands (egKeywords
This publication has 49 references indexed in Scilit:
- Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cellsBlood, 2009
- Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cellsBlood, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myelomaBlood, 2008
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cellsBlood, 2005
- IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activityInternational Journal of Clinical and Laboratory Research, 1997